Ausgabe 3/2003
Inhalt (12 Artikel)
Editorial
When should decision-analytic modeling be used in the economic evaluation of health care?
Uwe Siebert MDH, MPH
Original Papers
Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998–2001
Josep Darbà
Original Papers
A fuzzy logic approach toward solving the analytic enigma of health system financing
Dov Chernichovsky, Arkady Bolotin, David de Leeuw
Original Papers
Is therapeutic innovation responsible for the increase in drug expenditure?
Philippe Cavalié
Original Papers
Costs and effectiveness of a syringe distribution and needle exchange program for HIV prevention in a regional setting
Juan M. Cabasés, Eduardo Sánchez
Original Papers
Economic evaluation of human papillomavirus screening in Germany
T. Mittendorf, K. U. Petry, T. Iftner, W. Greiner, J. M. von der Schulenburg
Original Papers
Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK
Mike Aristides, Michael Lees, Nick Botwood, Jan McKendrick, Deborah A Stephenson, Nikos Maniadakis
Original papers
A single European currency for EQ-5D health states
Wolfgang Greiner, Tom Weijnen, Martin Nieuwenhuizen, Siem Oppe, Xavier Badia, Jan Busschbach, Martin Buxton, Paul Dolan, Paul Kind, Paul Krabbe, Arto Ohinmaa, David Parkin, Montserat Roset, Harri Sintonen, Aki Tsuchiya, Frank de Charro
Commentary
Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials"
Jon Karnon, A. Brennan, J. Chilcott